Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy
Objective: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic cerebral palsy, but its added value preceding comprehensive rehabilitation for motor impairments, gait, and goal attainment has not been studied. Design: A comparative multi-centre trial, i...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Foundation for Rehabilitation Information
2018-07-01
|
Series: | Journal of Rehabilitation Medicine |
Subjects: | |
Online Access: |
https://www.medicaljournals.se/jrm/content/html/10.2340/16501977-2369
|
id |
doaj-36e7da2cf31144a186e6964fd276de54 |
---|---|
record_format |
Article |
spelling |
doaj-36e7da2cf31144a186e6964fd276de542020-11-25T00:08:42ZengFoundation for Rehabilitation InformationJournal of Rehabilitation Medicine1650-19771651-20812018-07-0150873274210.2340/16501977-23692447Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsyFabienne Schasfoort0Robert PangalilaEmiel M. SneekesCoriene CatsmanJules BecherHerwin HoremansHenk J. StamAnnet J. DallmeijerJohannes B.J Bussmann Rehabilitation Medicine, Erasmus MC, 3000 CA Rotterdam, The Netherlands. f.schasfoort@erasmusmc.nl. Objective: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic cerebral palsy, but its added value preceding comprehensive rehabilitation for motor impairments, gait, and goal attainment has not been studied. Design: A comparative multi-centre trial, in which two groups underwent comprehensive rehabilitation (i.e. high-intensive functional physiotherapy, and indicated casting/orthoses). One group received intramuscular BoNT-A prior to rehabilitation, and the other group did not receive BoNT-A. Subjects/patients: Children with spastic cerebral palsy, Gross Motor Function Classification System (GMFCS) levels I–III, age range 4–12 years, indicated for BoNT-A treatment regarding mobility problems. Methods: Sixty-five children participated (37 boys), mean age 7.3 years (standard deviation (SD) 2.3, range 4–12 years), equally distributed across GMFCS levels. Forty-one children received BoNT-A+ comprehensive rehabilitation and 24 received comprehensive rehabilitation only. Functional leg muscle strength, passive range of motion, angle of catch, cerebral palsy-related pain, walking speed, kinematic gait parameters, goal attainment, and proxy-reported general functioning were assessed at baseline, primary end-point (12 weeks) and 24-week follow-up. Statistical analyses were performed with linear mixed models. Results: At the primary end-point there were no statistically significant differences in treatment effects between the groups, except for the angle-of-catch of the rectus femoris, which was in favour of comprehensive rehabilitation without BoNT-A (12° difference, 95% confidence interval (95% CI) 2:23, p = 0.025). Results at follow-up were similar. Conclusion: At the group level, treating with BoNT-A prior to comprehensive rehabilitation did not add to the clinical effectiveness of rehabilitation. Thus, BoNT-A prescription and use should be critically reconsidered in this cerebral palsy age- and GMFCS-subgroup. https://www.medicaljournals.se/jrm/content/html/10.2340/16501977-2369 spasticcerebralpalsybotulinumtoxinfunctionalphysiotherapycastingorthosesimpairmentsgoalattainmentpaediatricrehabilitation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Fabienne Schasfoort Robert Pangalila Emiel M. Sneekes Coriene Catsman Jules Becher Herwin Horemans Henk J. Stam Annet J. Dallmeijer Johannes B.J Bussmann |
spellingShingle |
Fabienne Schasfoort Robert Pangalila Emiel M. Sneekes Coriene Catsman Jules Becher Herwin Horemans Henk J. Stam Annet J. Dallmeijer Johannes B.J Bussmann Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy Journal of Rehabilitation Medicine spasticcerebralpalsy botulinumtoxin functionalphysiotherapy casting orthoses impairments goalattainment paediatricrehabilitation |
author_facet |
Fabienne Schasfoort Robert Pangalila Emiel M. Sneekes Coriene Catsman Jules Becher Herwin Horemans Henk J. Stam Annet J. Dallmeijer Johannes B.J Bussmann |
author_sort |
Fabienne Schasfoort |
title |
Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy |
title_short |
Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy |
title_full |
Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy |
title_fullStr |
Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy |
title_full_unstemmed |
Intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy |
title_sort |
intramuscular botulinum toxin prior to comprehensive rehabilitation has no added value for improving motor impairments, gait kinematics and goal attainment in walking children with spastic cerebral palsy |
publisher |
Foundation for Rehabilitation Information |
series |
Journal of Rehabilitation Medicine |
issn |
1650-1977 1651-2081 |
publishDate |
2018-07-01 |
description |
Objective: Botulinum toxin (BoNT-A) is widely used in combined treatment for spastic cerebral palsy, but its added value preceding comprehensive rehabilitation for motor impairments, gait, and goal attainment
has not been studied.
Design: A comparative multi-centre trial, in which two groups underwent comprehensive rehabilitation (i.e. high-intensive functional physiotherapy, and indicated casting/orthoses). One group received intramuscular BoNT-A prior to rehabilitation, and the other group did not receive BoNT-A.
Subjects/patients: Children with spastic cerebral palsy, Gross Motor Function Classification System (GMFCS) levels I–III, age range 4–12 years, indicated for BoNT-A treatment regarding mobility problems.
Methods: Sixty-five children participated (37 boys), mean age 7.3 years (standard deviation (SD) 2.3, range 4–12 years), equally distributed across GMFCS levels. Forty-one children received BoNT-A+ comprehensive rehabilitation and 24 received comprehensive rehabilitation only. Functional leg muscle strength, passive range of motion, angle of catch, cerebral palsy-related pain, walking speed, kinematic gait parameters, goal attainment, and proxy-reported general functioning were assessed at baseline, primary end-point (12 weeks) and 24-week follow-up.
Statistical analyses were performed with linear mixed models.
Results: At the primary end-point there were no statistically significant differences in treatment effects between the groups, except for the angle-of-catch of the rectus femoris, which was in favour of comprehensive rehabilitation without BoNT-A (12° difference, 95% confidence interval (95% CI) 2:23, p = 0.025). Results at follow-up were similar.
Conclusion: At the group level, treating with BoNT-A prior to comprehensive rehabilitation did not add to the clinical effectiveness of rehabilitation. Thus, BoNT-A prescription and use should be critically reconsidered in this cerebral palsy age- and GMFCS-subgroup. |
topic |
spasticcerebralpalsy botulinumtoxin functionalphysiotherapy casting orthoses impairments goalattainment paediatricrehabilitation |
url |
https://www.medicaljournals.se/jrm/content/html/10.2340/16501977-2369
|
work_keys_str_mv |
AT fabienneschasfoort intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy AT robertpangalila intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy AT emielmsneekes intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy AT corienecatsman intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy AT julesbecher intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy AT herwinhoremans intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy AT henkjstam intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy AT annetjdallmeijer intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy AT johannesbjbussmann intramuscularbotulinumtoxinpriortocomprehensiverehabilitationhasnoaddedvalueforimprovingmotorimpairmentsgaitkinematicsandgoalattainmentinwalkingchildrenwithspasticcerebralpalsy |
_version_ |
1725414933232877568 |